Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
REPH Recro Pharma		$1.73	$1.38 ▼ $3.79	$117.93M	1.08	126,298 shs	141,800 shs
SAGE Sage Therapeutics	$9.12 -0.3%	$7.41	$4.62 ▼ $13.47	$572.98M	0.18	1.29 million shs	2.72 million shs
STOK Stoke Therapeutics	$11.35 -2.4%	$10.27	$5.35 ▼ $16.15	$634.96M	1.09	675,566 shs	509,358 shs
TBPH Theravance Biopharma	$11.03 -1.7%	$10.03	$7.44 ▼ $11.82	$561.02M	-0.09	268,518 shs	208,255 shs

7 AI Stocks to Invest in Today: Capitalizing on AI and Tech Trends in 2025

Discover the top 7 AI stocks to invest in right now. This exclusive report highlights the companies leading the AI revolution and shaping the future of technology in 2025.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
REPH Recro Pharma	0.00%	0.00%	0.00%	0.00%	0.00%
SAGE Sage Therapeutics	0.00%	-1.61%	+40.77%	+15.09%	-15.75%
STOK Stoke Therapeutics	0.00%	+0.43%	+21.02%	+74.89%	-13.92%
TBPH Theravance Biopharma	0.00%	+5.55%	+21.30%	+25.64%	+32.31%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
REPH Recro Pharma	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
SAGE Sage Therapeutics	3.1885 of 5 stars	2.0	2.0	0.0	4.0	2.5	1.7	0.6
STOK Stoke Therapeutics	3.9864 of 5 stars	3.6	0.0	0.0	4.8	2.5	0.8	1.3
TBPH Theravance Biopharma	1.996 of 5 stars	3.3	0.0	0.0	0.0	2.6	2.5	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
REPH Recro Pharma	0.00	N/A	N/A	N/A
SAGE Sage Therapeutics	2.00	Hold	$8.93	-2.05% Downside
STOK Stoke Therapeutics	3.29	Buy	$23.20	104.41% Upside
TBPH Theravance Biopharma	2.67	Moderate Buy	$16.60	50.50% Upside

Current Analyst Ratings Breakdown

Latest REPH, STOK, SAGE, and TBPH Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
6/27/2025	TBPH Theravance Biopharma	BTIG Research Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$24.00 ➝ $25.00
6/20/2025	SAGE Sage Therapeutics	Robert W. Baird Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Neutral ➝ Neutral	$7.00 ➝ $9.00
6/17/2025	SAGE Sage Therapeutics	Piper Sandler Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Strong-Buy ➝ Hold	$9.00 ➝ $8.50
6/17/2025	SAGE Sage Therapeutics	Truist Financial Subscribe to MarketBeat All Access for the recommendation accuracy rating	Set Price Target	Hold ➝ Hold	$8.00 ➝ $9.00
6/17/2025	SAGE Sage Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Neutral ➝ Neutral	$12.00
6/17/2025	SAGE Sage Therapeutics	Canaccord Genuity Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Hold ➝ Hold	$8.00 ➝ $8.50
6/17/2025	TBPH Theravance Biopharma	Jones Trading Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy	$24.00
6/16/2025	SAGE Sage Therapeutics	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Hold ➝ Hold
5/14/2025	STOK Stoke Therapeutics	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy
5/14/2025	STOK Stoke Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$47.00 ➝ $35.00
4/25/2025	SAGE Sage Therapeutics	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Hold ➝ Hold

(Data available from 6/30/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
REPH Recro Pharma	$75.36M	0.00	N/A	N/A	$0.90 per share	0.00
SAGE Sage Therapeutics	$41.24M	13.85	N/A	N/A	$7.60 per share	1.20
STOK Stoke Therapeutics	$190.91M	3.25	N/A	N/A	$4.32 per share	2.63
TBPH Theravance Biopharma	$64.38M	8.57	N/A	N/A	$3.57 per share	3.09

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
REPH Recro Pharma	-$11.37M	-$0.31	N/A	N/A	N/A	-15.15%	-56.66%	-11.14%	N/A
SAGE Sage Therapeutics	-$400.67M	-$5.80	N/A	N/A	N/A	-747.63%	-68.99%	-60.67%	7/30/2025 (Estimated)
STOK Stoke Therapeutics	-$88.98M	$0.79	14.37	N/A	N/A	26.33%	19.08%	15.72%	8/5/2025 (Estimated)
TBPH Theravance Biopharma	-$56.42M	-$1.18	N/A	31.51	N/A	-89.38%	-32.37%	-16.48%	8/4/2025 (Estimated)

Latest REPH, STOK, SAGE, and TBPH Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue	Details
5/8/2025	Q1 2025	TBPH Theravance Biopharma	-$0.11	-$0.27	-$0.16	-$0.27	$28.08 million	$15.39 million
4/29/2025	Q1 2025	SAGE Sage Therapeutics	-$0.99	-$1.01	-$0.02	-$1.01	$14.12 million	$14.06 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
REPH Recro Pharma	N/A	N/A	N/A	N/A	N/A
SAGE Sage Therapeutics	N/A	N/A	N/A	N/A	N/A
STOK Stoke Therapeutics	N/A	N/A	N/A	N/A	N/A
TBPH Theravance Biopharma	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
REPH Recro Pharma	2.27	3.24	2.74
SAGE Sage Therapeutics	N/A	9.13	9.13
STOK Stoke Therapeutics	N/A	8.41	8.41
TBPH Theravance Biopharma	N/A	4.77	4.77

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
REPH Recro Pharma	62.34%
SAGE Sage Therapeutics	99.22%
STOK Stoke Therapeutics	N/A
TBPH Theravance Biopharma	99.10%

Insider Ownership

Company	Insider Ownership
REPH Recro Pharma	14.20%
SAGE Sage Therapeutics	5.50%
STOK Stoke Therapeutics	9.50%
TBPH Theravance Biopharma	6.90%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
REPH Recro Pharma	185	56.42 million	48.41 million	Optionable
SAGE Sage Therapeutics	690	62.62 million	59.18 million	Optionable
STOK Stoke Therapeutics	100	54.60 million	49.41 million	Optionable
TBPH Theravance Biopharma	359	50.00 million	46.55 million	Optionable

REPH, STOK, SAGE, and TBPH Headlines

Recent News About These Companies

BTIG Research Forecasts Strong Price Appreciation for Theravance Biopharma (NASDAQ:TBPH) Stock

June 29 at 2:07 AM | americanbankingnews.com

Theravance Biopharma (NASDAQ:TBPH) Trading 5.7% Higher on Analyst Upgrade

June 28 at 2:09 AM | americanbankingnews.com

Theravance Biopharma (NASDAQ:TBPH) Trading Up 5.7% on Analyst Upgrade

June 27 at 12:55 PM | marketbeat.com

Theravance Biopharma (NASDAQ:TBPH) Price Target Raised to $25.00 at BTIG Research

June 27 at 11:16 AM | marketbeat.com

TBPH Theravance Biopharma, Inc. - Seeking Alpha

June 26, 2025 | seekingalpha.com

Theravance Biopharma Announces Approval of YUPELRI® (revefenacin) by China's NMPA

June 26, 2025 | prnewswire.com

Theravance Biopharma (NASDAQ:TBPH) Upgraded by Wall Street Zen to "Buy" Rating

June 21, 2025 | marketbeat.com

Theravance Biopharma, Inc. (NASDAQ:TBPH) Receives $11.33 Average PT from Analysts

June 20, 2025 | americanbankingnews.com

Theravance Biopharma (NASDAQ:TBPH) Shares Gap Up - Still a Buy?

June 17, 2025 | marketbeat.com

Theravance Biopharma, Inc. (NASDAQ:TBPH) Receives Average Rating of "Hold" from Analysts

June 17, 2025 | marketbeat.com

Theravance Biopharma (NASDAQ:TBPH) Earns Buy Rating from Analysts at Jones Trading

June 17, 2025 | marketbeat.com

Theravance Biopharma (NASDAQ:TBPH) Shares Cross Above 50 Day Moving Average - What's Next?

June 17, 2025 | marketbeat.com

UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Buys 32,534 Shares of Theravance Biopharma, Inc. (NASDAQ:TBPH)

June 9, 2025 | marketbeat.com

Theravance Biopharma, Inc. (NASDAQ:TBPH) SVP Rhonda Farnum Sells 24,000 Shares

June 5, 2025 | marketbeat.com

Insider Selling: Theravance Biopharma, Inc. (NASDAQ:TBPH) SVP Sells 24,000 Shares of Stock

June 5, 2025 | insidertrades.com

Public Employees Retirement System of Ohio Takes $353,000 Position in Theravance Biopharma, Inc. (NASDAQ:TBPH)

June 5, 2025 | marketbeat.com

Squarepoint Ops LLC Sells 51,783 Shares of Theravance Biopharma, Inc. (NASDAQ:TBPH)

June 5, 2025 | marketbeat.com

TBPH to Sell Remaining Trelegy Royalty Interest to GSK, Stock Rises

June 3, 2025 | zacks.com

Theravance Biopharma (NASDAQ:TBPH) Hits New 52-Week High - Time to Buy?

June 3, 2025 | marketbeat.com

Theravance Biopharma, Inc. (NASDAQ:TBPH) Shares Bought by Millennium Management LLC

June 3, 2025 | marketbeat.com

Theravance Shares Rise Premarket on Sale of Trelegy Royalties

June 2, 2025 | marketwatch.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

REPH, STOK, SAGE, and TBPH Company Descriptions

Recro Pharma NASDAQ:REPH

Recro Pharma, Inc. is a pharmaceutical company, which engages in the contract development and manufacturing organization (CDMO). The firm offers integrated solutions for formulation, analytical services, regulatory support, manufacturing and packaging of both commercial and development stage oral solid dose drug products. The company was founded by Geraldine A. Henwood and Thomas F. Henwood on November 15, 2007 and is headquartered in Exton, PA.

Sage Therapeutics NASDAQ:SAGE

$9.12 -0.03 (-0.33%)

As of 04:00 PM Eastern

Sage Therapeutics, Inc., a biopharmaceutical company, develops and commercializes brain health medicines. Its product candidates include ZULRESSO, a CIV injection for the treatment of postpartum depression (PPD) in adults; and ZURZUVAE, a neuroactive steroid, a positive allosteric modulator of GABAA receptors, targeting both synaptic and extrasynaptic GABAA receptors, for the treatment of postpartum depression. Its product pipeline also comprises SAGE-324, a compound that is in Phase II clinical trial to treat essential tremors, as well as has completed Phase I clinical trial for epilepsy and Parkinson's diseases; and SAGE-718, an oxysterol-based positive allosteric modulator of the NMDA receptor, which is in Phase II clinical trial for the treatment of depression, Huntington's disease, Parkinson's diseases, Alzheimer's disease, attention deficit hyperactivity disorder, schizophrenia, and neuropathic pain. The company has a strategic collaboration with Shionogi & Co., Ltd. for the development and commercialization of zuranolone in Japan, Taiwan, and South Korea; and a collaboration and license agreement with Biogen MA Inc. to jointly develop and commercialize SAGE-217 and SAGE-324 products. The company was formerly known as Sterogen Biopharma, Inc. and changed its name to Sage Therapeutics, Inc. in September 2011. Sage Therapeutics, Inc. was incorporated in 2010 and is headquartered in Cambridge, Massachusetts.

Stoke Therapeutics NASDAQ:STOK

$11.35 -0.28 (-2.41%)

As of 04:00 PM Eastern

Stoke Therapeutics, Inc., an early-stage biopharmaceutical company, develops medicines to treat the underlying causes of severe genetic diseases in the United States. The company utilizes its proprietary targeted augmentation of nuclear gene output to develop antisense oligonucleotides to selectively restore protein levels. Its lead clinical candidate is STK-002, which is in preclinical stage for the treatment of autosomal dominant optic atrophy. The company also develops STK-001, which is in phase I/II clinical trial to treat Dravet syndrome; and programs focused on multiple targets, including haploinsufficiency diseases of the central nervous system and eye. The company has a license and collaboration agreement with Acadia Pharmaceuticals Inc. for the discovery, development, and commercialization of novel RNA-based medicines for the treatment of severe and rare genetic neurodevelopmental diseases of the central nervous system. The company was formerly known as ASOthera Pharmaceuticals, Inc. and changed its name to Stoke Therapeutics, Inc. in May 2016. Stoke Therapeutics, Inc. was incorporated in 2014 and is headquartered in Bedford, Massachusetts.

Theravance Biopharma NASDAQ:TBPH

$11.03 -0.19 (-1.69%)

As of 04:00 PM Eastern

Theravance Biopharma, Inc. is a diversified biopharmaceutical company primarily focused on the discovery, development and commercialization of organ-selective medicines. Its purpose is to pioneer a new generation of small molecule drugs designed to better meet patient needs. Its research is focused in the areas of inflammation and immunology. In pursuit of its purpose, Theravance Biopharma applies insights and innovation at each stage of its business and utilizes its internal capabilities and those of partners around the world. The Company applies organ-selective expertise to target disease biologically, to discover and develop medicines that may expand the therapeutic index with the goal of maximizing efficacy and limiting systemic side effects. These efforts leverage years of experience in developing lung-selective medicines to treat respiratory disease, including FDA-approved YUPELRI® (revefenacin) inhalation solution indicated for the maintenance treatment of patients with chronic obstructive pulmonary disease (COPD). Its pipeline of internally discovered programs is targeted to address significant patient needs. Theravance Biopharma has an economic interest in potential future payments from Glaxo Group Limited or one of its affiliates (GSK) pursuant to its agreements with Innoviva, Inc. relating to certain programs, including TRELEGY. For more information, please visit www.theravance.com.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time